Purpose: To study the results of retreatment after myopic photorefractive keratectomy in 22 patients. Five patients showed regression and 17 showed undercorrection combined with regression. The follow-up was 6 to 18 months.
Methods: A laser was used with a fluence of 160 mJ/cm2 at a frequency of 5 Hz. The same nomogram used for the initial treatment was used for the retreatment. No nitrogen purge was used. Fluorometholone 0.1% four times daily tapered over 4 months was applied postoperatively except in five patients.
Results: There was no untoward effect in any patient who had retreatment. The mean preoperative spherical equivalent before retreatment was -2.61 +/- 1.62 diopters (D) (range, -1.00 to -6.63 D). After 1 year, the mean spherical equivalent was -0.84 +/- 1.22 D (range, 0.00 to -4.88 D) and at 18 months it was -1.31 +/-1.60 D (range, 0.00 to -5.13 D). Spherical equivalent was +/- D in 82% of patients at 1 year and in 67% at 18 months. Uncorrected visual acuity was 20/40 or better at 1 year in 77% of patients and 20/20 or better in 55%; at 18 months, it was 20/40 or better in 67%.
Conclusion: Retreatment may be considered for undercorrection and/or regression in photorefractive keratectomy. No complications were observed, and there is appreciable improvement in the final results. The refraction 6 months after retreatment is stable with no statistically significant change from 6 to 12 months (Student's t=0.51; P=0.62) and 6 to 18 months (Student's t=1.0l; P=0.33).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0161-6420(96)30673-8 | DOI Listing |
Exp Eye Res
January 2025
Department of Ophthalmology, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address:
The study aimed to compare the effects of different types of excimer laser keratectomy on rabbit corneas and to identify the optimal disease model for corneal ectasia. Additionally, investigating the structural and molecular alterations in the novel disease model helped explore the mechanisms underlying biomechanical cues in corneal ectasia. 2.
View Article and Find Full Text PDFGenes (Basel)
January 2025
The Cornea Dystrophy Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemungu, Seoul 03722, Republic of Korea.
(1) Background: The phenotypes of classic lattice corneal dystrophy (LCD) and granular corneal dystrophy type 2 (GCD2) that result from abnormalities in gene () have previously been described. The phenotype of compound heterozygous classic LCD and GCD2, however, has not yet been reported. (2) Case report: A 39-year-old male (proband) presented to our clinic complaining of decreased vision bilaterally.
View Article and Find Full Text PDFCornea
January 2025
Institut für Refraktive und Ophthalmo-Chirurgie (IROC), Zurich, Switzerland.
Purpose: To describe a three-phase surgical approach for managing progressive visual decline in a patient with myopia magna and a history of epikeratophakia.
Methods: A 55-year-old woman with previous epikeratophakia surgery in both eyes experienced progressive visual deterioration. The three-phase approach included: (1) removal of the epikeratophakia lenticule, (2) cataract extraction with intraocular lens implantation, and (3) transepithelial topography-guided photorefractive keratectomy (trans-PRK).
Cureus
December 2024
Department of Ophthalmology, The University of Jordan, Amman, JOR.
We present the case of a 23-year-old male who experienced vision loss in his left eye 15 months after undergoing bilateral transepithelial photorefractive keratectomy (T-PRK). Despite the absence of any significant preoperative topographical risk factors in either eye, corneal ectasia was later confirmed in the left eye, while the right eye remained normal. Subtle asymmetry in topometric indices and a borderline high Index of vertical asymmetry (IVA) reading suggested the possibility of early subclinical keratoconus, potentially increasing the risk of post-refractive ectasia.
View Article and Find Full Text PDFBiomed Pharmacother
January 2025
The Cole Eye Institute, The Cleveland Clinic, Cleveland, OH 44195, United States. Electronic address:
Several studies in rabbits demonstrated the efficacy and safety of topical losartan, an angiotensin II receptor blockers (ARB) that modulates the TGF-β intracellular signaling pathways by inhibiting the activation of Extracellular Signal-regulated Kinase (ERK), in preventing or treating stromal fibrosis after a range of injuries such as Descemetorhexis, alkali burns, incisions, and photorefractive keratectomy (PRK). Several case reports have shown that topical losartan treatment is also efficacious and safe in humans to prevent or treat stromal fibrosis after many different injuries or diseases. Topical losartan penetrates the full thickness of the cornea and, therefore, can treat both anterior and posterior stromal fibrosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!